Nahdi Medical Co. reported a net profit after Zakat and tax of SAR 237.5 million for Q1 2022, a 22% increase from a profit of SAR 195 million in the same period a year earlier.
| Item | Q1 2021 | Q1 2022 | Change |
|---|---|---|---|
| Revenues | 1,981.11 | 2,079.49 | 5.0 % |
| Gross Income | 779.71 | 851.73 | 9.2 % |
| Operating Income | 224.35 | 255.15 | 13.7 % |
| Net Income | 195.02 | 237.51 | 21.8 % |
| Average Shares | 130.00 | 130.00 | - |
| EPS (Riyals) | 1.50 | 1.83 | 21.8 % |
| Item | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Revenues | 1,973.23 | 2,079.49 | 5.4 % |
| Gross Income | 807.21 | 851.73 | 5.5 % |
| Operating Income | 99.44 | 255.15 | 156.6 % |
| Net Income | 143.23 | 237.51 | 65.8 % |
| Average Shares | 130.00 | 130.00 | - |
| EPS (Riyals) | 1.10 | 1.83 | 65.8 % |
The profit increase is attributed to higher sales from the pharmaceuticals segment amid a rise in coronavirus Omicron variant cases. Also, infection rates increased compared to 2021, with the easing of the related restrictions.
The firm’s gross profit also increased on sales growth and positive product mix.
Sequentially, the company’s net profit grew 65.8% from SAR 143.2 million in Q4 2021.
Total shareholders’ equity stood at SAR 1.84 billion as of March 31, 2022, declining by 19.1% from SAR 2.27 billion a year earlier.
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}